An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
Recruiting in Palo Alto (17 mi)
+150 other locations
Age: < 18
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Bristol-Myers Squibb
No Placebo Group
Approved in 4 Jurisdictions
Trial Summary
What is the purpose of this trial?
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
Research Team
BS
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
Inclusion Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Diagnosis of JIA (any subtype)
Age < 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept
See 2 more
Treatment Details
Interventions
- Abatacept (Immunomodulator)
Abatacept is already approved in Canada, Japan for the following indications:
Approved in Canada as Orencia for:
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
Approved in Japan as Orencia for:
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Hospital for Sick ChildrenToronto, Canada
Vanderbilt University Medical CenterNashville, TN
Children's MercyKansas City, MO
Cincinnati Children's Hospital Medical CenterCincinnati, OH
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Trials
2731
Patients Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia